ABSTRACT
<b>Objective:</b> The aim of the present study was to investigate the differencesbetween therapeutic granulocyte-colony stimulating factor (G-CSF) cycles and prophylacticG-CSF cycles in patients receiving paclitaxel and carboplatin combination chemotherapy forovarian cancer.<br><b>Material and Method:</b> Medical records of 15 women who received paclitaxel andcarboplatin combination chemotherapy for ovarian cancer between January 2003 and December2012 were analyzed retrospectively. All 15 patients completed 6 cycles of paclitaxel andcarboplatin as the first-line chemotherapy. The complications were compared betweentherapeutic G-CSF cycles and prophylactic G-CSF cycles.<br><b>Results:</b> The number of chemotherapy cycles correlated with the ratio ofprophylactic G-CSF cycles. It was considered that earlier prophylactic G-CSF injectionswere chosen due to a gradual decrease in WBC and neutrophil counts. The WBC and neutrophilcounts were significantly higher in prophylactic G-CSF cycles than in therapeutic G-CSFcycles. However, there were no significant differences in the intervals of chemotherapy,delay of chemotherapy, and incidence of febrile neutropenia between the therapeutic G-CSFand prophylactic G-CSF cycles.<br><b>Conclusion:</b> Prophylactic G-CSF injections were not effective in preventingthe incidence of febrile neutropenia in patients receiving paclitaxel and carboplatincombination chemotherapy for ovarian cancer.
ABSTRACT
Objective: To investigate unfavorable prognostic factors in advanced ovarian cancer.Materials and Methods: The medical records of 15 women diagnosed with advanced ovarian cancer between January 2003 and December 2009 were examined. We compared some factors between the complete first-line chemotherapy group and the incomplete first-line chemotherapy group, and between the complete SLO/SDS group and the incomplete SLO/SDS group. Moreover, we performed multivariate analysis of prognostic factors.Results: The mean age of women in the incomplete first-line chemotherapy group was significantly advanced than that in the complete first-line chemotherapy group. The CA125 value for the complete SLO/SDS group was significantly lower than that for the incomplete SLO/SDS group. Multivariate analysis, found that advanced age, incomplete first-line chemotherapy and poor declined CA125 value were unfavorable prognostic factors in advanced ovarian cancer.Discussion: From advanced aged women with advanced ovarian cancer, it is necessary to obtain informed consent. As the case may be, we should consider providing neoadjuvant chemotherapy and palliative medicine. To those patients with incomplete first-line chemotherapy and poor declined CA125 value, we should tell them that they could choose second-line chemotherapy and palliative medicine.Conclusion: It was found that advanced age, incomplete first-line chemotherapy and poor declined CA125 value, were unfavorable prognostic factors. In cases with these three factors, we should supply them with adequate information and treatment cautiously.